跳至主要内容
临床试验/NCT03879564
NCT03879564已完成4 期

Efficacy of Ketamine-fentanyl VS Fentanyl for Analgosedation in Postoperative Ventilated SICU Patients

Mahidol University1 个研究点 分布在 1 个国家目标入组 118 人开始时间: 2019年4月5日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
118
试验地点
1
主要终点
fentanyl consumption

研究概览

简要总结

This is a randomized, double-blinded study to evaluate the analgosedative effect of ketamine in a surgical intensive care unit. The patients who will receive continuous fentanyl infusion for either pain control or sedation will be recruited in this trial. Fentanyl will be titrated with initial loading doses of 20 mcg until the numeral rating scale(NRS) less than 4 or critical care pain observation tool (CPOT) less than 3 or Richmond agitation sedation score (RASS) -2-0. Then the patients will be randomised in to receive saline infusion in control group (Group C) or ketamine infusion in ketamine group (Group K). Ketamine will be administered with an initial bolus of 0.3 mg/kg followed by a perfusion of1.5 mcg/kg/min during the first 48 h. The dose of fentanyl will be protocolized adjusted according to NRS or CPOT or RASS. We tested the research hypothesis that low-doseketamine infusion is associated with a reduced fentanyl dose without increased vulnerability to its psychotropic effects.

详细描述

Upon SICU admission, patient eligibility will be assessed, and informed consent will be obtained. A fentanyl bolus will be titrated by attending physicians to reach the target of patients' NRS pain scores at < 4 (self-report) or CPOT scores < 3 (unable to self-report pain) or patients' Richmond agitation and sedation scale (RASS) scores between -2 and 0.

After enrollment, patients will be randomly assigned in a 1:1 ratio by their sequential number of enrollment to receive either ketamine infusion (Group K) or placebo (Group C) together with fentanyl at 20 mcg/hr, initially. Randomization will be performed using a computer-generated randomization table derived from www.randomization.com. This process will be performed by an investigator (K.W.) who has no other role in patient enrollment or management. The other investigators, the patients, the patients' relatives, the attending physicians, and the nurses will all blinded to the study assignment. The study drug (ketamine or placebo) will be prepared by a pharmacist, who has no other role in the trial. The study drugs are packaged in identically shaped containers labeled with sequential numbers according to the randomization table order. For the study drug, 50 mg of ketamine is mixed with 50 ml of 0.9% NaCl (NSS), giving a final ketamine concentration of 1 mg/ml. For the placebo comparator, 50 ml of NSS will be prepared. The study drug will infuse via either peripheral line or central venous catheter (when available) at an individually adjusted rate according to the patient's body weight to achieve a dose of ketamine of 1.5 mcg/kg/min. The study drug will infuse for a period of 48 hours or until discontinue if narcotic medication without titration in both groups.

All eligible patients will receive narcotic and sedative medication according to the pain and sedation protocol. This included infusion of narcotic medication (fentanyl) and sedative medication to keep target NRS scores at < 4 and RASS scores between 0 and -2. Additional 20-mcg fentanyl IV bolus every 10 minutes will be administrated if needed. If more than 2 boluses are given per hr, the fentanyl rate will be increased by 10 mcg/hr to achieve pain and sedation goals. Blinded nurses will record pain scores, RASS, and medication doses every 4 hours.

Fentanyl IV infusion will be held if the RASS score is less than -2, indicating oversedation. If fentanyl is not administered for over one hour and the patient's RASS score remained below -2, the study drug will be discontinued.

A telephone follow-up will be conducted 12-60 months after ICU discharge using the Thai version of the Posttraumatic Symptom Scale (PTSS-10 questionnaire) to screen for the occurrence of PTSD as well as traumatic memories in the ICU. The interviews will be conducted by a research team unaware of the patients' group assignment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

ketamine and normal saline will be filled in 50-ml syringe and will be administered in the same condition

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Older than 18 years.
  • Need ICU care
  • Need continuous iv fentanyl as an sedative of analgesia drug

排除标准

  • Pregnant women
  • Known allergy to ketamine
  • Severe cardiovascular disorders (ejection fraction< 30%, acute myocardial infarction, decompensated heart failure, significant tachyarrhythmia)
  • Acute psychosis
  • coma patient
  • Renal insufficiency (creatinine clearance < 30 mL/min)
  • Unable to assess pain with either NRS or CPOT
  • Neurosurgery/ CVT patients/ trauma patients

研究组 & 干预措施

control

Placebo Comparator

0.9% NaCl IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr

干预措施: Normal saline (Drug)

ketamine

Experimental

ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr

干预措施: Ketamine (Drug)

结局指标

主要结局

fentanyl consumption

时间窗: 24 hours after initial fentanyl infusion

the amount of fentanyl in microgram/kg in the patients who receive ketamine compare with who receive NSS

次要结局

  • ICU length of stay(30 days after admitted to ICU)
  • Psychomimetic adverse effects(72 hours after admitted to ICU)
  • Duration of mechanical ventilation(30 days after admitted to ICU)
  • bowel motility(72 hours after admitted to ICU)
  • cardiovascular effect(72 hours after admitted to ICU)
  • Long-term effect(12 to 60 months after ICU discharge)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Karuna Wongtangman

principle investigator

Mahidol University

研究点 (1)

Loading locations...

相似试验